Key Points
- CEO Joseph Belanoff sold 26,198 shares on March 25 at an average price of $50.07 for proceeds of $1,311,733.86, trimming his stake by 0.89% to 2,918,326 shares valued at about $146.1 million (SEC filing).
- FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer is a material commercial catalyst that triggered a sharp rally and has led brokers to raise ratings and price targets.
- Corcept missed the recent quarter (EPS $0.20 vs. $0.33 expected; revenue $202.1M vs. $254.9M), and mixed analyst views plus ongoing litigation and insider selling have contributed to heightened volatility and investor uncertainty.
Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) CEO Joseph Belanoff sold 26,198 shares of Corcept Therapeutics stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $50.07, for a total value of $1,311,733.86. Following the completion of the sale, the chief executive officer owned 2,918,326 shares of the company's stock, valued at approximately $146,120,582.82. The trade was a 0.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Corcept Therapeutics Trading Down 2.4%
NASDAQ:CORT opened at $37.60 on Friday. The business's 50-day moving average price is $37.53 and its two-hundred day moving average price is $60.69. Corcept Therapeutics Incorporated has a 1-year low of $28.66 and a 1-year high of $117.33. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of 45.85 and a beta of 0.29. The company has a current ratio of 2.92, a quick ratio of 2.85 and a debt-to-equity ratio of 0.01.
Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.13). The business had revenue of $202.13 million during the quarter, compared to analyst estimates of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The firm's revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.26 earnings per share. On average, equities analysts expect that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.
Wall Street Analyst Weigh In
Several research analysts recently commented on the company. Truist Financial raised Corcept Therapeutics to a "strong-buy" rating in a research report on Wednesday. Canaccord Genuity Group increased their price target on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the company a "buy" rating in a report on Thursday. Wolfe Research raised Corcept Therapeutics from an "underperform" rating to a "peer perform" rating in a report on Thursday. HC Wainwright cut their price target on Corcept Therapeutics from $67.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Corcept Therapeutics in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Corcept Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $77.67.
Check Out Our Latest Report on Corcept Therapeutics
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Pathstone Holdings LLC raised its stake in shares of Corcept Therapeutics by 0.8% during the third quarter. Pathstone Holdings LLC now owns 18,013 shares of the biotechnology company's stock valued at $1,497,000 after acquiring an additional 144 shares during the last quarter. Campbell Newman Asset Management Inc. increased its position in Corcept Therapeutics by 0.5% in the 3rd quarter. Campbell Newman Asset Management Inc. now owns 35,530 shares of the biotechnology company's stock valued at $2,953,000 after buying an additional 170 shares in the last quarter. Clearstead Advisors LLC raised its position in shares of Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company's stock worth $26,000 after purchasing an additional 193 shares during the period. Gould Capital LLC raised its holdings in Corcept Therapeutics by 50.0% during the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company's stock worth $50,000 after buying an additional 200 shares during the last quarter. Finally, Advisors Asset Management Inc. raised its holdings in shares of Corcept Therapeutics by 1.3% in the 2nd quarter. Advisors Asset Management Inc. now owns 18,935 shares of the biotechnology company's stock worth $1,390,000 after acquiring an additional 237 shares during the last quarter. Institutional investors own 93.61% of the company's stock.
Corcept Therapeutics News Summary
Here are the key news stories impacting Corcept Therapeutics this week:
- Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer is a material commercial catalyst that triggered the earlier sharp rally; approval creates a new revenue pathway and is the primary reason investors re‑rated the stock this week. FDA approval report
- Positive Sentiment: Broker/analyst support: Wolfe Research upgraded CORT (from underperform to peer‑perform) and other brokers (Truist, Canaccord) have issued bullish/strong‑buy views or raised targets, which can sustain buying interest as the market models new sales upside. Wolfe Research upgrade
- Neutral Sentiment: Market structure/volatility: trading halts and large intraday prints accompanied the approval-driven move — expect continued high volume and price swings as investors reprice expectations for launch and uptake. Market reaction coverage
- Neutral Sentiment: Consensus/ratings mix: some outlets show a "moderate buy" brokerage consensus; analysts remain mixed on valuation as the market weighs launch potential vs. prior execution and study data. Broker consensus report
- Negative Sentiment: Legal risk: multiple law firms have filed shareholder alerts and class actions alleging that Corcept misled investors about regulatory issues and patent matters; these suits (and the referenced FDA rejection / federal court patent loss claims) create potential liability, discovery risk and distraction for management. Hagens Berman class‑action alert
- Negative Sentiment: Insider selling: a recent disclosed sale by an insider reduced holdings significantly; while not proof of negative outlook, such sales can weigh on sentiment when paired with litigation headlines. Insider sale filing
- Negative Sentiment: Analyst divergence / forecast cuts: some firms have tempered long‑term estimates or issued cautious notes (e.g., a pessimistic forecast from HC Wainwright in recent coverage), underscoring uncertainty around peak sales and reimbursement. HC Wainwright coverage
About Corcept Therapeutics
(
Get Free Report)
Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.
The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
